AcuCort signs exclusive Canadian licensing and distribution deal with Kye Pharmaceuticals for Zeqmelit

• AcuCort signed an exclusive licensing and distribution agreement with Kye Pharmaceuticals for Zeqmelit, its fast-dissolving dexamethasone oral film, in Canada.
• Kye gains exclusive Canadian rights to register, market, distribute and sell the drug.
• Financial terms include upfront and milestone payments, product supply revenue and royalties on Kye's net sales.
• A regulatory filing is planned for early 2027, with launch expected in 2028 subject to Health Canada approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202611090230BITN____UKPR__SV_20261108-BIT-6318-0) on November 09, 2026, and is solely responsible for the information contained therein.